Browse the evidence

GLP-1 receptor agonists improve cardiovascular risk factors (blood pressure, lipid profiles, endothelial function) and reduce cardiovascular events in patients with type 2 diabetes and obesity.

GLP-1 injections not only help with weight and blood sugar but also improve heart health by lowering blood pressure, improving cholesterol, and reducing inflammation. They are recommended for patients with T2DM and obesity to reduce cardiovascular risk.

Statins are safe and effective as first-line treatment for hyperlipidemia in MASLD patients, despite under-prescription, and may reduce cardiovascular events and liver disease burden.

If you have MASLD and high cholesterol or CVD risk, ask your doctor about statins. They are safe for your liver, even if you have some liver scarring, and are the first-line treatment to lower your risk of heart disease. Do not avoid them due to fear of liver damage.

Tirzepatide treatment significantly reduces the 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) in adults with obesity or overweight without diabetes compared to placebo.

If you have obesity or overweight without diabetes, treatment with tirzepatide (a once-weekly injection) combined with lifestyle changes can significantly lower your calculated 10-year risk of heart disease compared to placebo. This benefit was observed across different baseline risk levels, suggesting it may be a valuable option for long-term cardiovascular health improvement in this population.

SGLT-2 inhibitors reduce body weight (0.9-2.5 kg) and improve cardiovascular and renal outcomes in patients with diabesity by inducing glycosuria, making them a valuable class of medication for managing both metabolic and organ-specific risks.

SGLT-2 inhibitors (like Jardiance or Farxiga) are oral diabetes medications that also help with modest weight loss (1-2.5 kg) and protect your heart and kidneys. They work by removing excess sugar through urine. While this can increase the risk of yeast infections or UTIs, good hygiene and doctor guidance can manage this. They are particularly beneficial if you have heart or kidney risks associated with your diabetes.

GLP-1 receptor agonists for obesity treatment cause significant loss of lean body mass (including muscle) and bone density, with muscle loss accounting for approximately 20% of total weight reduction in the absence of structured resistance training.

If you are taking GLP-1s for weight loss, you must incorporate resistance training (weight lifting or bodyweight exercises) at least 2-3 times per week. Without this, roughly 20% of the weight you lose will be muscle, not just fat. Ensure you are eating enough protein to support muscle retention during the caloric deficit.

Rapid and substantial weight reduction via GLP-1 therapy increases the risk of nutrient deficiencies and bone density loss, particularly when caloric intake drops below 1200 kcal/day for females or 1800 kcal/day for males without nutritional counseling.

Monitor your caloric intake. If you are eating less than 1200 calories (women) or 1800 calories (men) per day, you must prioritize nutrient-dense foods or consider a multivitamin/mineral supplement to prevent deficiencies in iron, calcium, vitamin D, and B12. Avoid rapid weight loss (>14% in 3-4 months) if possible to protect bone density.

Short-term caloric restriction is insufficient for managing obesity because it fails to target the underlying mechanisms of the disease, whereas personalized, lifelong nutrition management is required.

Avoid 'diets' that end after a few weeks. Focus on a personalized, sustainable eating pattern that you can maintain for life to manage your weight and metabolic health.

Continuous Glucose Monitoring (CGM) is a mainstay of diabetes management that improves glycemic control by tracking time in range and tailoring drug regimens, and serves as a motivational tool for lifestyle choices.

If you have diabetes, ask about Continuous Glucose Monitoring (CGM). It helps you and your doctor adjust medications and see how food and exercise affect your blood sugar in real-time.

Lifestyle interventions (diet and physical activity) alone result in modest weight loss (2-9%) and are often insufficient for significant health improvements, though they remain a fundamental component of obesity management.

Lifestyle changes are essential but often result in only modest weight loss (2-9%) that is hard to maintain. For significant health improvements, lifestyle changes should be combined with other treatments like medications or surgery, especially if you have obesity-related health conditions.

GLP-1 receptor agonists for obesity treatment cause significant loss of lean body mass (approximately 38% of total weight loss) and muscle mass, increasing the risk of sarcopenia and bone loss, particularly in the absence of structured resistance training and adequate protein intake.

If you are taking a GLP-1 medication for weight loss, expect to lose some muscle along with fat. To protect your strength and metabolism, you must prioritize resistance training (weight lifting or bodyweight exercises) and ensure you are eating enough protein. Without these steps, you risk losing significant muscle mass, which can happen with any rapid weight loss method.

Discontinuation of GLP-1 therapy for obesity leads to significant weight regain (up to two-thirds of lost weight within one year), even when accompanied by conventional nutritional counseling, highlighting the need for long-term lifestyle support.

If you stop taking your GLP-1 medication, you will likely regain a significant portion of the weight you lost, even if you try to eat well. This is because the medication helps manage hunger signals that return when you stop taking it. To maintain your weight loss, you need a robust, long-term lifestyle plan, not just standard diet advice, and you may need to stay on the medication long-term.

GLP-1 therapy for obesity increases the risk of nutritional deficiencies (e.g., iron, calcium, vitamins A, D, E, K, B1, B12, C) due to significant reductions in caloric intake and potential GI side effects that impair absorption.

Because GLP-1s make you eat much less, you might not get enough essential vitamins and minerals. Watch for signs like fatigue, hair loss, or poor wound healing. Prioritize nutrient-dense foods (vegetables, lean proteins, whole grains) and discuss with your doctor whether you need specific supplements, especially if your calorie intake is very low.

Short-term muscle disuse atrophy (4 days) in humans is driven by declines in muscle protein synthesis (MPS), not by increased muscle protein breakdown (MPB).

If you are immobilized or inactive for a few days, your muscle loss is caused by a drop in your body's ability to build new muscle protein, not by an increase in muscle destruction. To mitigate this, interventions should focus on stimulating muscle protein synthesis (e.g., through protein intake or resistance stimuli if possible) rather than just trying to block breakdown pathways.

The hypertrophic benefit of creatine supplementation is modestly greater in younger adults compared to older adults, although the effect remains small in both groups.

Younger lifters may see a slightly better muscle growth boost from creatine than older lifters, but the difference is small. Older adults should still use creatine as it provides a small benefit, even if the magnitude is lower than in youth.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) provide a net health benefit for weight loss in non-diabetic adults with obesity, but only when the treatment goal is achieving ≥10% body weight loss; achieving 5% weight loss results in a net harm due to side effects.

If you are considering GLP-1 medications for weight loss without diabetes, understand that these drugs are most effective and 'worth it' if you aim to lose 10% or more of your body weight. Losing only 5% may actually result in a net negative health outcome due to side effects like nausea and vomiting. Ensure you are committed to lifestyle changes (diet and exercise) alongside the medication, and discuss your specific weight loss goals and tolerance for side effects with your doctor.

Polyphenols and unsaturated fats in the Mediterranean diet mitigate metabolic syndrome risk by suppressing proinflammatory cytokines and lipid peroxidation.

Use extra virgin olive oil as your primary fat source. It contains polyphenols that reduce inflammation and improve metabolic health, countering the negative effects of saturated and trans fats found in Western diets.

SGLT-2 inhibitors and DPP-4 inhibitors produce modest or neutral weight loss effects, respectively, making them less effective for weight management compared to GLP-1 agonists.

SGLT-2 inhibitors offer modest weight loss (3-5%), while DPP-4 inhibitors are generally weight-neutral or have mild effects. They are less effective for weight management than GLP-1 agonists. SGLT-2 inhibitors work by excreting glucose in urine, but compensatory mechanisms limit weight loss. DPP-4 inhibitors are better suited for glycemic control without significant weight impact.

Behavioral weight management interventions (WLs and WLMs) generally do not exacerbate health inequalities, as most trials find no significant gradient in uptake, adherence, or outcomes across socioeconomic and demographic groups.

Most behavioral weight loss programs work similarly across different social groups. If you are from a disadvantaged background, do not assume the program will fail you; most evidence shows no difference in outcome compared to advantaged groups. However, if you do struggle with adherence, it may be because the program requires high personal agency (time/education) which might be a barrier for you.

Weight loss outcomes (kg or % loss) in behavioral interventions do not consistently favor either 'more' or 'less' advantaged groups, with most trials finding no significant difference in weight loss by socioeconomic or demographic status.

Your socioeconomic background does not predict your weight loss success. While you might face more barriers to starting or sticking with a program, if you do complete it, you are likely to lose the same amount of weight as anyone else.

Intensive glucose-lowering strategies in type 2 diabetes significantly reduce the risk of non-fatal myocardial infarction and microvascular complications (retinopathy, nephropathy) compared to standard therapy, but do not significantly reduce major adverse cardiovascular events (MACE) or all-cause mortality.

For people with Type 2 Diabetes, aiming for very low blood sugar levels (intensive control) is beneficial for protecting your eyes and kidneys, and may slightly reduce the risk of non-fatal heart attacks. However, it does not significantly reduce the risk of major heart events, stroke, or death compared to standard control. Therefore, intensive glucose lowering should be combined with aggressive management of blood pressure and lipids, rather than being the sole focus for heart health.

GLP-1 receptor agonists (GLP-1RAs) significantly improve liver enzymes (AST, ALT, GGT) and reduce fibrosis scores in patients with MAFLD and T2DM, though they are not recommended as a primary treatment for NASH histology in the absence of diabetes.

If you have type 2 diabetes and fatty liver, GLP-1 medications (like Semaglutide) can significantly improve your liver enzymes and reduce scarring markers. They are recommended by guidelines for this specific group. However, they can cause stomach issues like nausea, which leads many people to stop taking them. Discuss with your doctor if the benefits for your liver and heart outweigh the side effects.

Daily supplementation with a combination of nicotinamide riboside (NR) and pterostilbene (NRPT) at the recommended dose significantly reduces circulating levels of hepatic inflammation markers (ALT and GGT) and toxic lipids (ceramide 14:0) in adults with Non-Alcoholic Fatty Liver Disease (NAFLD) over 6 months, without reducing hepatic fat fraction.

If you have NAFLD, a specific combination of Nicotinamide Riboside and Pterostilbene (taken daily at the recommended dose) may help lower liver inflammation markers (ALT, GGT) and toxic lipids over 6 months. However, do not expect this supplement to reduce the actual amount of fat in your liver, as the study showed no improvement in hepatic fat fraction compared to a placebo.

Obesity is associated with high prevalence of micronutrient deficiencies (e.g., Vitamin D, Iron, B12) due to physiological changes like increased volume of distribution, sequestration in adipose tissue, and inflammation-induced malabsorption (e.g., hepcidin blocking iron).

If you have obesity, assume you may be deficient in key micronutrients like Vitamin D, Iron, and B12, regardless of how much you eat. Focus on nutrient-dense foods and discuss screening with your doctor, as standard weight loss diets can sometimes worsen these deficiencies.

Strict weight reduction diets (Low-carb, Ketogenic, Intermittent Fasting, VLCD) significantly increase the risk of micronutrient deficiencies compared to balanced or low-fat diets.

If you use a restrictive diet like Keto or Intermittent Fasting to lose weight, you are at high risk for missing essential nutrients. You must actively supplement or carefully plan your meals to include these nutrients, as the diet itself limits your intake.